

# Alan Dal Pra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3184620/publications.pdf>

Version: 2024-02-01

77  
papers

2,565  
citations

361413  
20  
h-index

206112  
48  
g-index

77  
all docs

77  
docs citations

77  
times ranked

4929  
citing authors

#	ARTICLE	IF	CITATIONS
1	Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. <i>Advances in Radiation Oncology</i> , 2022, 7, 100832.	1.2	4
2	Clinicogenomic characterization of prostate cancer liver metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 366-369.	3.9	7
3	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 80-91.	0.8	5
4	Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 718-724.	0.8	6
5	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	1.9	93
6	Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. <i>Medical Physics</i> , 2021, 48, 2386-2399.	3.0	13
7	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. <i>Journal of Urology</i> , 2021, 205, 1344-1351.	0.4	5
8	Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5010-5010.	1.6	3
9	Assessment of Knowledge-Based Planning for Prostate Intensity Modulated Proton Therapy. <i>International Journal of Particle Therapy</i> , 2021, 8, 62-72.	1.8	8
10	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021, 258-259, 61-68.	0.4	2
11	Assessment of daily dose accumulation for robustly optimized intensity modulated proton therapy treatment of prostate cancer. <i>Physica Medica</i> , 2021, 81, 77-85.	0.7	4
12	The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103497.	4.4	17
13	Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 3139-3144.	1.9	14
14	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. <i>Physica Medica</i> , 2020, 77, 154-159.	0.7	11
15	Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020, 10, 617302.	2.8	5
16	Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>Eur Urol</i> 2020;78:661-669. <i>European Urology</i> , 2020, 78, e221-e222.	1.9	0
17	Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20200028.	2.2	16
18	The role of radiomics in prostate cancer radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 900-912.	2.0	24

#	ARTICLE	IF	CITATIONS
19	Segmentation of prostate and prostate zones using deep learning. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 932-942.	2.0	36
20	Shifting the Curtainâ€”Can We Make Sense of the Whole Pelvis Controversy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 534-536.	0.8	9
21	Using hormone therapy with salvage radiotherapy according to presalvage PSA levels. <i>Nature Reviews Urology</i> , 2020, 17, 489-490.	3.8	0
22	Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?. <i>Journal of Clinical Oncology</i> , 2020, 38, 9579-9579.	1.6	2
23	Re: GaÃ«tan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? <i>Eur Urol</i> 2019;76:265â€“7. <i>European Urology</i> , 2019, 76, e148-e149.	1.9	0
24	Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. <i>Radiation Oncology</i> , 2019, 14, 177.	2.7	13
25	Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2019, 9, 12.	2.8	17
26	Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and Selection. <i>European Urology</i> , 2019, 75, 419-422.	1.9	1
27	Can texture analysis of pre-immunotherapy CT imaging predict clinical outcomes for patients with advanced NSCLC treated with Nivolumab?. <i>Journal of Clinical Oncology</i> , 2019, 37, e20720-e20720.	1.6	2
28	Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 9-16.	2.0	14
29	Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>Eur Urol</i> 2017;72:910â€“7. <i>European Urology</i> , 2018, 73, e34-e35.	1.9	1
30	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. <i>Radiation Oncology</i> , 2018, 126, 257-262.	0.6	19
31	Contemporary role of postoperative radiotherapy for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 399-413.	1.4	5
32	Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. <i>Radiation Oncology</i> , 2018, 13, 216.	2.7	46
33	Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. <i>Translational Andrology and Urology</i> , 2018, 7, 445-458.	1.4	26
34	An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 821-829.	0.8	16
35	Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 223.	4.4	60
36	SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS157-TPS157.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017, 541, 359-364.	27.8	462
38	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
39	T1-2 glottic cancer treated with radiotherapy and/or surgery. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 995-1004.	2.0	23
40	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 982-995.	0.8	56
41	Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?. <i>Radiation Oncology</i> , 2017, 12, 102.	2.7	3
42	Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 275.	2.8	0
43	Abstract A28: Mutational landscape of TP53 in localized prostate cancer. , 2017, , .		0
44	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 24.	2.8	20
45	Urethral strictures after radiation therapy for prostate cancer. <i>Investigative and Clinical Urology</i> , 2016, 57, 309.	2.0	15
46	Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. <i>Eur Urol</i> 2016;69:50-7 Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. <i>Eur Urol</i> 2016;69:58-9. <i>European Urology</i> , 2016, 69, e74-e75.	1.9	0
47	Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2016, 46, 35-41.	7.7	20
48	Prostate cancer radiation therapy: A physician's perspective. <i>Physica Medica</i> , 2016, 32, 438-445.	0.7	22
49	Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. <i>British Journal of Radiology</i> , 2016, 89, 20160217.	2.2	43
50	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. <i>Radiation Oncology</i> , 2016, 11, 48.	2.7	12
51	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. <i>Journal of Clinical Oncology</i> , 2016, 34, e80-e83.	1.6	1
52	Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes - A systematic review. <i>Radiotherapy and Oncology</i> , 2016, 119, 185-193.	0.6	21
53	Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. <i>European Urology</i> , 2016, 70, 31-32.	1.9	4
54	Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 300-308.	1.9	14

#	ARTICLE	IF	CITATIONS
55	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 117-117.	1.6	0
56	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. Journal of Clinical Oncology, 2016, 34, 96-96.	1.6	0
57	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. Journal of Clinical Oncology, 2016, 34, 49-49.	1.6	0
58	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5051-5051.	1.6	0
59	Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture. , 2016, , .		0
60	Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745.	21.4	395
61	Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland. Strahlentherapie Und Onkologie, 2015, 191, 778-786.	2.0	18
62	Definitive intensity modulated radiotherapy in locally advanced hypopharyngeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. Radiation Oncology, 2015, 10, 20.	2.7	8
63	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews Urology, 2015, 12, 193-204.	3.8	41
64	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. European Urology Focus, 2015, 1, 173-184.	3.1	11
65	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	10.7	291
66	Objective consensus from decision trees. Radiation Oncology, 2014, 9, 270.	2.7	40
67	In Regard to Freedland et al. International Journal of Radiation Oncology Biology Physics, 2014, 88, 237-240.	0.8	4
68	Intratumoral Hypoxia as the Genesis of Genetic Instability and Clinical Prognosis in Prostate Cancer. Advances in Experimental Medicine and Biology, 2014, 772, 189-204.	1.6	28
69	Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical Cancer Research, 2013, 19, 6741-6750.	7.0	268
70	Does transperitoneal minimally invasive radical prostatectomy increase the amount of small bowel receiving salvage radiation?. Canadian Urological Association Journal, 2013, 7, 444.	0.6	2
71	<i>TMPRSS2-ERG</i> Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research, 2013, 19, 5202-5209.	7.0	39
72			

#	ARTICLE	IF	CITATIONS
73	TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 11-11.	1.6	0
74	Association of tumor hypoxia with lower survival after radiotherapy for muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2012, 30, 292-292.	1.6	0
75	Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. Radiotherapy and Oncology, 2011, 101, 486-489.	0.6	14
76	Stereotactic Fractionated Radiotherapy in the Treatment of Juxtapapillary Choroidal Melanoma: The McGill University Experience. International Journal of Radiation Oncology Biology Physics, 2011, 81, e455-e462.	0.8	24
77	Radiation therapy and androgen deprivation in the management of high risk prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 161-179.	1.5	15